Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

1. Toja-Camba, F.J.
2. García-Quintanilla, L.
3. Rodríguez-Martinez, L.
4. Tomine, J.
5. Cajade-Pascual, F.
6. Feitosa, C.
7. Zarra-Ferro, I.
8. Barreiro-De-Acosta, M.
9. González-López, J.
10. Mondelo-García, C.
11. Fernández-Ferreiro, A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.3390/PHARMACEUTICS15112615 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus